Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib as adjuvant therapy in EGFR-mutated NSCLC
NCT07182682Phase 3Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07182682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182682.